Electrode catheter with incremental advancement

Information

  • Patent Grant
  • 11678932
  • Patent Number
    11,678,932
  • Date Filed
    Monday, May 15, 2017
    6 years ago
  • Date Issued
    Tuesday, June 20, 2023
    10 months ago
Abstract
Apparatus comprises: (a) a longitudinal member (32), having a distal portion (34); (b) a plurality of electrodes (38) disposed on the distal portion of the longitudinal member, such that a first electrode (38a) of the plurality of electrodes is disposed distally along the longitudinal member from a second electrode (38b) of the plurality of electrodes; and (c) a controller (40). The controller comprises an actuator, and circuitry (42) electrically connected to the electrodes via the longitudinal member. The actuator is configured to move the longitudinal member in discrete incremental movements such that for each incremental movement, (i) before the incremental movement the first electrode is disposed in a starting position, (ii) during each incremental movement the actuator moves second electrode toward the starting position, and (iii) at the end of each incremental movement the second electrode is stationary at the starting position.
Description
FIELD OF THE INVENTION

Applications of the present invention relate generally to ablation of tissue. Some applications of the present invention relate more specifically to ablation of tissue of the renal artery.


BACKGROUND

Hypertension is a prevalent condition in the general population, particularly in older individuals. Sympathetic nervous pathways, such as those involving the renal nerve, are known to play a role in regulating blood pressure. Ablation of renal nerve tissue from the renal artery is a known technique for treating hypertension.


SUMMARY OF THE INVENTION

Apparatus and methods are provided for improving nerve ablation procedures, including inter alia by reducing the number of steps, the number of movements, and/or the amount of time required. The apparatus and methods may be particularly useful for renal nerve ablation procedures. For some applications, ablative current is applied by one electrode and excitatory current is applied by another electrode, without it being necessary to move the electrodes. The electrodes are then moved in a stepwise procession through the artery with which the nerve is associated.


Also described are techniques for applying current to the wall of an artery in a manner that emulates monopolar current application, but without the use of a skin-based return electrode.


There is therefore provided, in accordance with an application of the present invention, a method, including:


advancing into a blood vessel of a subject a distal portion of a longitudinal member having a plurality of electrodes disposed thereon, such that a first electrode of the plurality of electrodes is disposed at a starting position, the first electrode being disposed, along the distal portion, distally to a second electrode of the plurality of electrodes;


using a controller to drive the first electrode to apply an ablative current;


using the controller to drive the second electrode to apply an excitatory current; and


subsequently, moving the longitudinal member distally such that the second electrode moves toward the starting position of the first electrode, and stops at the starting position of the first electrode.


In an application, the distal portion of the longitudinal member has an operational shape in which it is curved to define a helix, the plurality of electrodes are distributed in a helical arrangement along the distal portion of the longitudinal member, and the step of moving the longitudinal member distally includes moving the longitudinal member distally and rotating at least the distal portion of the longitudinal member such that the second electrode moves toward the starting position of the first electrode, and stops at the starting position of the first electrode.


In an application, the method further includes, subsequently to the step of moving the longitudinal member:


using the controller to drive the first electrode to apply an ablative current to tissue distal to the starting position of the first electrode; and


using the controller to drive the second electrode to apply an excitatory current to tissue at the starting position of the first electrode.


There is further provided, in accordance with an application of the present invention, apparatus for use with a blood vessel of a subject, the apparatus including:


a longitudinal member, having a distal portion that is transluminally advanceable into the blood vessel;


a plurality of electrodes disposed on the distal portion of the longitudinal member, such that a first electrode of the plurality of electrodes is disposed distally along the longitudinal member from a second electrode of the plurality of electrodes; and a controller, including:

    • circuitry electrically connected to the electrodes via the longitudinal member, and
    • an actuator, mechanically connected to the longitudinal member, and configured to move the longitudinal member in discrete incremental movements such that for each incremental movement, (a) before the incremental movement the first electrode is disposed in a starting position, (b) during each incremental movement the actuator moves second electrode toward the starting position of the first electrode, and (c) at the end of each incremental movement the second electrode is stationary at the starting position of the first electrode.


In an application:


the plurality of electrodes includes a third electrode and a fourth electrode,


the third electrode is disposed distally along the longitudinal member from the fourth electrode, and


the actuator is configured to move the longitudinal member in incremental movements such that for each incremental movement, (a) before the incremental movement the third electrode is disposed in a starting position, (b) during each incremental movement the actuator moves fourth electrode toward the starting position of the third electrode, and (c) at the end of each incremental movement the fourth electrode is stationary at the starting position of the third electrode.


In an application:


the plurality of electrodes includes a third electrode and a fourth electrode,


the third electrode is disposed distally along the longitudinal member from the fourth electrode, and


the actuator is configured to move the longitudinal member in incremental movements such that for each incremental movement, (a) before the incremental movement the third electrode is disposed in a starting position, (b) during each incremental movement the actuator moves fourth electrode toward the starting position of the third electrode, and (c) at the end of each incremental movement the fourth electrode is stationary at the starting position of the third electrode,


wherein the circuitry is configured to, after each incremental movement, drive the first and third electrodes to apply ablative current, and to drive the second and fourth electrodes to apply excitatory current.


In an application, the distal portion of the longitudinal member has an operational shape in which it is curved to define a helix, the plurality of electrodes is distributed in a helical arrangement along the distal portion of the longitudinal member, and the actuator is configured to move the second electrode into the starting position of the first electrode by advancing and rotating the longitudinal member.


In an application, the actuator includes a servomotor.


In an application, the circuitry is configured to drive the first electrode to apply ablative current, and to drive the second electrode to apply excitatory current.


In an application, the circuitry is configured to drive the first electrode to apply ablative current, and to drive the second electrode to apply excitatory current after each incremental movement.


In an application, the circuitry is configured to configure the ablative current to have a frequency of 450-550 kHz.


In an application, the circuitry is configured to configure the excitatory current to have a frequency of 20-500 Hz.


In an application, the circuitry is configured to drive the first electrode to apply the ablative current independently from driving the excitatory current.


There is further provided, in accordance with an application of the present invention, apparatus for use with a blood vessel of a subject, the apparatus including:


a longitudinal member, having a distal portion that is transluminally advanceable into the blood vessel;


a plurality of electrodes disposed on the distal portion of the longitudinal member; and


a controller, including circuitry electrically connected to the electrodes via the longitudinal member, and having:

    • a first state in which the controller drives one of the electrodes to apply ablative current, and configures the other electrodes not to serve as return electrodes for the ablative current, and
    • a second state in which the controller drives one of the electrodes to apply ablative current, and configures more than one of the other electrodes to serve as return electrodes for the ablative current.


In an application, the distal portion of the longitudinal member has an operational shape in which it is curved to define a helix, and the plurality of electrodes are distributed in a helical arrangement along the distal portion of the longitudinal member.


In an application, the controller has a third state in which the controller drives one of the electrodes to apply ablative current, and configures more than one of the other electrodes to serve as return electrodes for the ablative current, wherein one of the electrodes that serves as a return electrode in the third state is the electrode that in the second state the controller drives to apply ablative current.


In an application, the electrode that in the first state the controller drives to apply ablative current is the same electrode as the electrode that in the second state the controller drives to apply ablative current.


In an application, the controller has another state in which the controller drives one of the electrodes to apply ablative current, and configures only one of the other electrodes to serve as a return electrode for the ablative current.


In an application, in the first state, the controller is configured to configure the ablative current to have a frequency of 450-550 kHz, and a power of 1-7 W.


The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A, 1B, 1C, and 1D are schematic illustrations of a method for use with a blood vessel of a subject, in accordance with some applications of the invention;



FIGS. 2A and 2B are schematic illustrations of a system for use with a blood vessel of a subject, in accordance with some applications of the invention; and



FIGS. 3A, 3B, and 3C are schematic illustrations of a system for use with a blood vessel of a subject, in accordance with some applications of the invention.





DETAILED DESCRIPTION OF EMBODIMENTS

It is possible to use an excitatory current (i.e., a current configured to induce action potentials in nerve tissue) in order to locate renal nerves, and to monitor the progress of ablation of these nerves. Changes in one or more physiological parameters of the subject in response to the excitatory current indicate that the electrode used to apply the excitatory current is in proximity to a renal nerve, and that renal nerve is still at least partly functioning. Such parameters are typically related to blood pressure and/or heart rate. Techniques for locating and/or monitoring ablation of renal nerves (and other nerves) are described in the following patent applications, which are incorporated herein by reference:

    • PCT application publication WO 2014/068577 to Gross et al., filed Nov. 3, 2013, and entitled “Controlled tissue ablation,”
    • PCT application publication WO 2015/170281 to Gross et al., filed May 7, 2015, and entitled “Controlled tissue ablation techniques,”
    • U.S. patent application Ser. No. 14/794,737 to Gross et al., filed Jul. 8, 2015, and entitled “Electrical signal-based electrode-tissue contact Detection,” which published as US 2017/0007157,
    • U.S. patent application Ser. No. 14/972,756 to Gross et al., filed Dec. 17, 2015, and entitled “Transluminal electrode catheters, which published as US 2017/0172651”
    • U.S. patent application Ser. No. 15/001,615 to Gross et al., filed Jan. 20, 2016, and entitled “Catheter guidance and procedure planning, which published as US 2017/0202614” and
    • U.S. patent application Ser. No. 15/147,081 to Gross et al., filed May 5, 2016 and entitled “Techniques for use with nerve tissue,” which published as US 2016/0324572.


Such techniques may be time-consuming, e.g., because multiple excitations and/or ablations are typically required, because frequent repositioning of the electrode catheter is typically required, and because it is typically necessary to allow the parameter(s) being measured to return to baseline before the next application of current.


Reference is made to FIGS. 1A-D, which are schematic illustrations of a method for use with a blood vessel (e.g., a renal artery) 10 of a subject, in accordance with some applications of the invention. The method is hypothesized to reduce the number of steps required for a nerve-locating and/or nerve-ablating procedure by facilitating the application of ablative and excitatory current to artery 10 without movement of the electrode catheter. The method involves iteratively moving an electrode (e.g., an excitatory electrode) into the position within artery 10 that another electrode previously occupied.


An electrode catheter 30 comprises a longitudinal member 32, which has a distal portion 34 that is transluminally advanceable into blood vessel 10, and a proximal portion 36. Catheter 30 further comprises a plurality of electrodes 38 (e.g., a first electrode 38a, a second electrode 38b, a third electrode 38c, and a fourth electrode 38d) disposed on distal portion 34, typically distributed along member 32. For example, electrode 38a is disposed distally along longitudinal member 32 from electrode 38b. For example, along distal portion 34, electrode 38a is disposed distally to electrode 38b, which is disposed distally to electrode 38c, which is disposed distally to electrode 38d.


It is to be noted that, although catheter 30 is shown having four electrodes, for some applications the catheter comprises a different number of electrodes, such as two, three, five, six, seven, eight, or more. Similarly, although the helical shape of distal portion 34 is shown as having one helical turn, it may have more than one helical turn. Catheter 30 may in fact have more than one helical turn with more than four electrodes arranged in more than one helical turn along distal portion 34.


Distal portion 34 of longitudinal member 32 is advanced into blood vessel 10, such that a first electrode 38a of the plurality of electrodes is disposed at a starting position 12 of that electrode (FIG. 1A). (It is to be noted that the term “starting position” (including in the specification and in the claims) does not necessarily mean the first position in which the electrode is disposed after entering artery 10.) A controller 40 comprises control circuitry 42, which is electrically connected to electrodes 38 via longitudinal member 32. Controller 40 is used (e.g., by an operating physician) (i) to drive electrode 38a to apply an ablative current (i.e., to tissue adjacent to the electrode), and (ii) to drive electrode 38b to apply an excitatory current (i.e., to tissue adjacent to the electrode). The ablative and excitatory currents are therefore applied while catheter 30 and its electrodes remain in the same position. For some applications, the ablative and excitatory currents are applied generally at the same time. For some applications, the ablative and excitatory currents are applied independently of each other. A response of one or more physiological parameters to the excitatory current is measured.


Controller 40 is typically a programmed digital computing device comprising a central processing unit (CPU), random access memory (RAM), non-volatile secondary storage, such as a hard drive or CD ROM drive, network interfaces, and/or peripheral devices. Program code, including software programs, and/or data are loaded into the RAM for execution and processing by the CPU and results are generated for display, output, transmittal, or storage, as is known in the art. Such program code and/or data, when provided to the controller, produce a machine or special-purpose computer, configured to perform the tasks described herein. Controller 40 further comprises a user interface (UI) 46 via which the operating physician interacts with (e.g., operates) the controller. For example, UI 46 may comprise one or more input devices (e.g., buttons and/or levers) and/or one or more output devices (e.g., dials and/or displays). For some applications, controller 40 is electrically connected to a blood pressure sensor (which may be disposed on longitudinal member 32; not shown), and receives blood pressure measurements, thereby facilitating the identification and/or quantification of the response of the one or more physiological parameters to the excitatory current.


Longitudinal member 32 is subsequently moved distally such that electrode 38b moves toward the starting position 12 of electrode 38a, and stops there (FIG. 1B). As shown, this also causes electrode 38a to move into a new position 14, electrode 38c to move into the starting position of electrode 38b, and electrode 38d to move into the starting position of electrode 38d. In this position, controller 40 is again used (i) to drive electrode 38a to apply an ablative current, and (ii) to drive electrode 38b to apply an excitatory current, and again, a response of one or more physiological parameters to the excitatory current is measured. As described hereinabove, the ablative and excitatory currents are applied while catheter 30 and its electrodes remain in the same position (and optionally generally at the same time). This reduces the number of steps (and therefore time) required, compared to a similar procedure in which it is necessary to move the electrode catheter between each application of current.



FIGS. 1C and 1D show further iterative steps in this process.


For some applications, the movement of longitudinal member 32 distally is performed manually. For some such applications, the longitudinal member (e.g., proximal portion 36 thereof) has markers that are spaced according to the spacing of electrodes 38, such that the operating physician can advance the longitudinal member by one marker, knowing that this will place each electrode in the position that was previously occupied by another electrode. For some applications (e.g., as described hereinbelow with reference to FIGS. 2A-B) the movement of longitudinal member 32 distally is at least partly automated.


For some applications, and as shown, distal portion 34 of longitudinal member 32 has an operational shape in which it is curved to define a helix, and electrodes 38, which are distributed along distal portion 34, are thereby distributed in a helical arrangement. This is hypothesized to facilitate ablation at many circumferential positions around artery 10, but without ablating in a closed circle, which for some applications may cause narrowing and/or weakening of the artery. For such applications, the step of moving the longitudinal member 32 distally comprises moving the longitudinal member distally and rotating at least distal portion 34 such that electrode 38b moves (e.g., in a helical path) toward the starting position of electrode 38a, and stops there.


For some applications, the step of moving longitudinal member 32 distally comprises moving the longitudinal member distally without rotating distal portion 34. For some such applications, distal portion 34 may be helical, as shown. Alternatively, for some such applications distal portion 34 may have a different form, such as a basket or balloon.


The above description of the method shown in FIGS. 1A-D relates to two electrodes. As described hereinabove, catheter 30 may comprise a different number of electrodes (e.g., four electrodes, as shown). The method described with reference to FIGS. 1A-D is also applicable to such numbers of electrodes. Two such applications are as follows:


(1) More proximal electrodes may be used to repeat the ablation-excitation process at a given site on artery 10. For example, if it is determined that the physiological parameter responds to the excitatory current applied by electrode 38b to starting position 12 (FIG. 1B), another application of ablative current may be applied via electrode 38c when it is disposed at position 12 (FIG. 1C), and another application of excitatory current may be subsequently applied via electrode 38d when that electrode is disposed at position 12 (FIG. 1D).


(2) More than one electrode may be used to apply a current. That is, application of the ablative and/or excitatory current may be performed in a bipolar manner. For example, ablative current may be applied between electrodes 38a and 38c, and excitatory current may be applied between electrodes 38b and 38d.


For some applications, the ablative current has a frequency of 450-550 kHz and/or a power of 1-7 W. For some applications, the ablative current has a sinusoidal waveform.


For some applications, the excitatory current has a frequency of 20-500 Hz and/or a stimulation amplitude of 1-50 mA. For some applications, the excitatory current has a rectangular waveform.


Reference is now made to FIGS. 2A-B, which are schematic illustrations of a system 20 for use with artery 10 of a subject, in accordance with some applications of the invention. System 20 comprises electrode catheter 30 and a controller 60 for the electrode catheter. Controller 60 is typically as described for controller 40, except where noted. System 20 is typically used to facilitate the method described with reference to FIGS. 1A-D, and/or methods similar thereto.


Controller 60 comprises control circuitry 62, which is electrically connected to electrodes 38 via longitudinal member 32. Controller 60 also comprises a user interface (UI) 66, via which the operating physician interacts with the controller. Controller 60 further comprises an actuator 64, which is mechanically connected to longitudinal member 32, and is configured to move the longitudinal member in discrete incremental movements such that for each incremental movement, (a) before the incremental movement the first electrode is disposed in a starting position, (b) during each incremental movement the actuator moves second electrode toward the starting position of the first electrode, and (c) at the end of each incremental movement the second electrode is stationary at the starting position of the first electrode.


In order to perform the movements of catheter 30 described with reference to FIGS. 1A-D, the operating physician triggers actuator 64 (e.g., via UI 66) such that the actuator moves longitudinal member 32 the discrete increment (e.g., distally, or distally and rotationally). The arrows in FIG. 2B show the movement of longitudinal member 32 and electrodes 38 during the discrete incremental movement that will occur when the operating physician next triggers actuator 64. Each incremental movement is typically pre-determined, e.g., based on known dimensions of longitudinal member 32 and spacing of electrodes 38. For some applications, actuator 64 comprises a servomotor. The use of controller 60 to automatically move the longitudinal member such that each electrode moves into the position that the electrode distal to it previously occupied, reduces the requirement for imaging (e.g., fluoroscopy) during the procedure.


The applications of ablative and excitatory currents are also typically applied by the operating physician via UI 66.


Reference is again made to FIGS. 1A-2B. For some applications, the electrodes are differently configured for application of ablative or excitatory currents. For some applications, all the electrodes are identical other than in their respective connection to the controller, which differentially drives the electrodes to apply the respective type of current.


Catheter 30 is described as having its distalmost electrode (electrode 38a) apply ablative current, and for the electrode proximal to that (electrode 38b) apply excitatory current. However, for some applications, the distalmost electrode applies excitatory current, and the electrode proximal to that applies ablative current. For example, the controller may drive electrode 38a to apply excitatory current, electrode 38b to apply ablative current, electrode 38c to apply excitatory current, and so on. For such applications, each site in artery 10 is thereby tested (by applying excitatory current and measuring the physiological response) before any ablative current is applied to it, thereby reducing the number of unnecessary applications of ablative current. An exemplary procedure may be as follows:


(1) Distal portion 34 of longitudinal member 32 is advanced into artery 10, electrode 38a is driven to apply excitatory current. If the physiological response to the excitatory current is insufficient or absent, the catheter is repositioned (e.g., advanced distally) and excitatory current is reapplied via electrode 38a, iteratively until a sufficient physiological response is detected, indicating that electrode 38a is in proximity to a viable renal nerve. For this example, let the position of electrode 38a in which it successfully excited the nerve, be called position A.


(2) Distal portion 34 is advanced distally such that electrode 38b moves to and stops at position A, and electrode 38a moves to and stops at a new position B.


(3) Electrode 38a is driven to apply excitatory current at position B, and electrode 38b is driven to apply ablative current at position A. Typically, distal portion 34 is not moved between the application of these two currents. For some applications, these two currents are applied at generally the same time. Therefore, electrode 38a tests position B, and electrode 38b ablates at position A, without it being necessary to move catheter 30 between these functions being performed.


(4) Distal portion 34 is advanced distally, such that electrode 38a moves to a new position C, electrode 38b moves to position B, and electrode 38c moves to position A.


(5) Electrode 38a is driven to apply excitatory current at position C, and electrode 38c is driven to apply excitatory current at position A. Additionally, if the previous excitation by electrode 38a at position B successfully affected the physiological parameter, then electrode 38b is driven to apply ablative current at position B. Typically, distal portion 34 is not moved between the application of these two or three currents. For some applications, these two or three currents are applied at generally the same time. Therefore, electrode 38a tests position C, electrode 38c re-tests position A (to see if the ablative current successfully denervated that location), and optionally electrode 38b ablates at position B, without it being necessary to move catheter 30 between these functions being performed.


These steps are iteratively repeated along the artery, e.g., to positions D, E, F, G, and so on. For applications in which another electrode, disposed proximally from electrode 38c, is configured to apply ablative current (e.g., electrode 38d), if the re-testing of position A by electrode 38c determines that the first ablation of position A by electrode 38a was unsuccessful, then this other electrode may be used to re-apply ablative current at position A. Increasing the number of ablating and exciting electrodes along distal portion 34 allows an increased number of re-testing and re-ablating steps using this technique.


Reference is made to FIGS. 3A-C, which are schematic illustrations of a system 70 for use with artery 10 of a subject, in accordance with some applications of the invention. System 70 comprises electrode catheter 30 and a controller 80 for the electrode catheter. Alternatively, system 70 may comprise a different electrode catheter. Controller 80 is typically as described for controller 60, except where noted. Controller 80 comprises control circuitry 82, which is electrically connected to electrodes 38 via longitudinal member 32. Controller 80 also comprises a UI 86, via which the operating physician interacts with the controller. Controller 80 may or may not comprise actuator 64 (described hereinabove).


Controller 80 has a first state in which it drives one of electrodes 38 to apply ablative current, and configures the other electrodes not to serve as return electrodes for the ablative current. (It is to be noted that in this context the terms first state, second state, third state etc. are used to facilitate reference to the different states, and should not be understood as implying a particular order in which these states occur or are used). FIG. 3A shows system 70 with controller 80 in the first state, driving electrode 38b to apply ablative current, with electrodes 38a, 38c, and 38d not serving as return electrodes. In the first state, a skin-mounted return electrode is typically used. The ablative current is represented by dotted arrows, moving deeper into the surrounding tissue, e.g., toward the skin-mounted return electrode. This is typically referred to as monopolar ablation.


It is understood by the inventors that for some sites within a particular renal artery, monopolar ablation is preferable, and for some sites, bipolar ablation is preferable. For some applications, this is determined during the excitation steps described hereinabove, and/or during procedures described in the patent applications cited hereinabove, and incorporated herein by reference.


Controller 80 has a second state in which it drives one of electrodes 38 to apply ablative current, and configures more than one of the other electrodes to serve as return electrodes for the ablative current. FIG. 3B shows system 70 with controller 80 in the second state, driving electrode 38b to apply ablative current, with electrodes 38a, 38c, and 38d serving as return electrodes. The ablative current is represented by dotted arrows, moving from electrode 38b toward the three return electrodes. In classical bipolar ablation, ablative current is driven between two electrodes, and current-density at the return electrode is typically similar to that at the current-applying electrode. Frequently, the resulting lesion may extend between the two electrodes, or a separate lesion may be formed at the return electrode. In the second state of controller 80, the current applied by the current-applying electrode (electrode 38b) spreads toward the more-than-one return electrodes, such that the current-density at each of the return electrodes is lower than at the current-applying electrode. It is hypothesized by the inventors that the effect of this technique is similar to that of monopolar ablation, but advantageously doesn't require a skin-mounted electrode. Control and reliability are improved because the distance and tissue between the current-applying electrode and the return electrodes is less variable than with a skin-mounted return electrode. Additionally, in contrast to bipolar ablation, the spreading of current to more than one return electrodes reduces a likelihood of causing extended and/or secondary lesions.


For some applications, the same electrode (as shown, electrode 38b) is driven to apply the ablative current in both the first and second states.


For some applications, controller 80 has a third state in which it drives one of electrodes 38 to apply ablative current, and configures more than one of the other electrodes to serve as return electrodes for the ablative current. One of the electrodes that serves as a return electrode in the third state is the electrode that in the second state controller 80 drives to apply ablative current. FIG. 3C shows system 70 with controller 80 in the third state, driving electrode 38c to apply ablative current, with electrode 38b serving as one of the return electrodes.


For some applications, controller 80 has another state in which only one of the other electrodes serves as a return electrode, thereby performing classical bipolar ablation.


Although the techniques described with reference to FIGS. 3A-C refer to application of ablative current, these same techniques may be used for application of excitatory current, mutatis mutandis.


Reference is again made to FIGS. 1A-3C. Although the apparatus and methods described herein are described for iteratively moving distal portion 34 in a distal direction (e.g., from an ostium of renal artery 10 toward a kidney), they may alternatively be used by moving the distal portion in a proximal direction, mutatis mutandis.


Reference is again made to FIGS. 1A-3C. Although not shown, distal portion 34 is typically drawn toward its central longitudinal axis (and thereby away from the wall of artery 10) before each movement being moved distally (or proximally) through the artery. For example, when distal portion 34 is helical, this is typically achieved by straightening the helix. For some applications, distal portion 34 is biased to assume a relatively straight shape, and assumes its helical shape upon insertion of a pre-shaped rod into the distal portion.


Reference is again made to FIGS. 1A-3C. For some applications electrodes 38 are rings that circumscribe longitudinal member 32. For some applications, electrodes 38 do not circumscribe longitudinal member 32, and instead are disposed on the longitudinal member such that when distal portion 34 assumes the helical shape, they are disposed radially outward from the longitudinal member such that they face the wall of the blood vessel.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus for use with a blood vessel of a subject, the apparatus comprising: a longitudinal member, having a distal portion that is transluminally advanceable into the blood vessel;a plurality of electrodes disposed on the distal portion of the longitudinal member, such that a first electrode of the plurality of electrodes is disposed distally along the longitudinal member from a second electrode of the plurality of electrodes, wherein the distal portion of the longitudinal member has an operational shape in which it is curved to define a helix, the plurality of electrodes is distributed in a helical arrangement along the distal portion of the longitudinal member; anda controller, comprising:circuitry electrically connected to the electrodes via the longitudinal member, andan actuator, mechanically connected to the longitudinal member, and configured to move the longitudinal member in discrete incremental movements distally and rotationally such that for each incremental movement, (a) before the incremental movement the first electrode is disposed in a starting position, (b) during each incremental movement the actuator moves second electrode toward the starting position of the first electrode, and (c) at the end of each incremental movement the second electrode is stationary at a location that is both longitudinally and laterally the same as the starting position of the first electrode;wherein the circuitry is configured to drive the first electrode to apply ablative current, and to drive the second electrode to apply excitatory current.
  • 2. The apparatus according to claim 1, wherein: the plurality of electrodes comprises a third electrode and a fourth electrode,the third electrode is disposed distally along the longitudinal member from the fourth electrode, andthe actuator is configured to move the longitudinal member in incremental movements such that for each incremental movement, (a) before the incremental movement the third electrode is disposed in a starting position, (b) during each incremental movement the actuator moves fourth electrode toward the starting position of the third electrode, and (c) at the end of each incremental movement the fourth electrode is stationary at the starting position of the third electrode.
  • 3. The apparatus according to claim 1, wherein: the plurality of electrodes comprises a third electrode and a fourth electrode,the third electrode is disposed distally along the longitudinal member from the fourth electrode, andthe actuator is configured to move the longitudinal member in incremental movements such that for each incremental movement, (a) before the incremental movement the third electrode is disposed in a starting position, (b) during each incremental movement the actuator moves fourth electrode toward the starting position of the third electrode, and (c) at the end of each incremental movement the fourth electrode is stationary at the starting position of the third electrode,wherein the circuitry is configured to, after each incremental movement, drive the first and third electrodes to apply ablative current, and to drive the second and fourth electrodes to apply excitatory current.
  • 4. The apparatus according to claim 1, wherein the actuator comprises a servomotor.
  • 5. The apparatus according to claim 1, wherein the circuitry is configured to drive the first electrode to apply ablative current, and to drive the second electrode to apply excitatory current after each incremental movement.
  • 6. The apparatus according to claim 1, wherein the circuitry is configured to configure the ablative current to have a frequency of 450-550 kHz.
  • 7. The apparatus according to claim 1, wherein the circuitry is configured to configure the excitatory current to have a frequency of 20-500 Hz.
  • 8. The apparatus according to claim 1, wherein the circuitry is configured to drive the first electrode to apply the ablative current independently from driving the excitatory current.
  • 9. A method for using the apparatus of claim 1, comprising: advancing into a blood vessel of a subject the distal portion of the longitudinal member having the plurality of electrodes disposed thereon, such that the first electrode of the plurality of electrodes is disposed at the starting position, the first electrode being disposed, along the distal portion, distally to the second electrode of the plurality of electrodes;using the controller to drive the first electrode to apply an ablative current;using the controller to drive the second electrode to apply an excitatory current; andsubsequently, moving the longitudinal member distally and rotating at least the distal portion of the longitudinal member such that the second electrode moves toward the starting position of the first electrode, and stops at the starting position of the first electrode.
  • 10. The method according to claim 9, further comprising, subsequently to the step of moving the longitudinal member: using the controller to drive the first electrode to apply an ablative current to tissue distal to the starting position of the first electrode; andusing the controller to drive the second electrode to apply an excitatory current to tissue at the starting position of the first electrode.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is the US National Phase of PCT application IL2017/050533 to Yossi GROSS et al., filed May 15, 2017, entitled “HELICAL CATHETER,” which published as WO 2017/199240, and which claims priority to U.S. provisional patent application 62/338,115 to Yossi GROSS et al., filed May 18, 2016, and entitled “HELICAL CATHETER,” which is incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/IL2017/050533 5/15/2017 WO
Publishing Document Publishing Date Country Kind
WO2017/199240 11/23/2017 WO A
US Referenced Citations (340)
Number Name Date Kind
4106488 Gordon Aug 1978 A
4569836 Gordon Feb 1986 A
4619247 Inoue Oct 1986 A
5215086 Terry, Jr. et al. Jun 1993 A
5251634 Weinberg Oct 1993 A
5697377 Wittkampf Dec 1997 A
5735280 Sherman et al. Apr 1998 A
5776063 Dittrich et al. Jul 1998 A
5807285 Vaitekunas Sep 1998 A
5817022 Vesely Oct 1998 A
5827216 Igo et al. Oct 1998 A
6050943 Slayton Apr 2000 A
6064902 Haissaguerre et al. May 2000 A
6117101 Diederich Sep 2000 A
6128523 Bechtold Oct 2000 A
6161048 Sluijter Dec 2000 A
6219577 Brown Apr 2001 B1
6233477 Chia May 2001 B1
6241727 Tu Jun 2001 B1
6246899 Chia Jun 2001 B1
6361500 Masters Mar 2002 B1
6405732 Edwards Jun 2002 B1
6425877 Edwards Jul 2002 B1
6440077 Jung Aug 2002 B1
6485431 Campbell Nov 2002 B1
6522926 Kieval Feb 2003 B1
6526318 Ansarinia Feb 2003 B1
6605084 Acker et al. Aug 2003 B2
6635054 Fjield et al. Oct 2003 B2
6641579 Bernardi Nov 2003 B1
6659950 Taheri Dec 2003 B2
6671556 Osorio et al. Dec 2003 B2
6684105 Cohen et al. Jan 2004 B2
6685639 Wang Feb 2004 B1
6692490 Edwards Feb 2004 B1
6701931 Sliwa et al. Mar 2004 B2
6736835 Pellegrino May 2004 B2
6740040 Mandrusov May 2004 B1
6805129 Pless et al. Oct 2004 B1
6845267 Harrison Jan 2005 B2
7001336 Mandrusov Feb 2006 B2
7022105 Edwards Apr 2006 B1
7037306 Podany et al. May 2006 B2
7149574 Yun Dec 2006 B2
7162303 Levin Jan 2007 B2
7226440 Gelfand et al. Jun 2007 B2
7311701 Gifford et al. Dec 2007 B2
7326201 Fjield et al. Feb 2008 B2
7430449 Aldrich Sep 2008 B2
7499747 Kieval Mar 2009 B2
7510536 Foley Mar 2009 B2
7553284 Vaitekunas Jun 2009 B2
7565191 Burbank et al. Jul 2009 B2
7608072 Swanson Oct 2009 B2
7617005 Demarais Nov 2009 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem Jan 2010 B2
7662099 Podany et al. Feb 2010 B2
7684865 Aldrich Mar 2010 B2
7706882 Francischelli Apr 2010 B2
7717948 Demarais May 2010 B2
7787946 Stahmann et al. Aug 2010 B2
7840271 Kieval Nov 2010 B2
7853333 Demarais Dec 2010 B2
7854733 Govari Dec 2010 B2
7901359 Mandrusov Mar 2011 B2
7974696 DiLorenzo Jul 2011 B1
8197409 Foley Jun 2012 B2
8391970 Tracey et al. Mar 2013 B2
8585601 Sverdlik et al. Nov 2013 B2
8696581 Sverdlik et al. Apr 2014 B2
8702619 Wang Apr 2014 B2
9014821 Wang Apr 2015 B2
9028417 Sverdlik et al. May 2015 B2
9381063 Gang et al. Jul 2016 B2
9408549 Brockway et al. Aug 2016 B2
9439598 Shimada et al. Sep 2016 B2
9566456 Sverdlik et al. Feb 2017 B2
9770593 Gross Sep 2017 B2
9999463 Puryear et al. Jun 2018 B2
10004557 Gross Jun 2018 B2
10383685 Gross et al. Aug 2019 B2
10478249 Gross et al. Nov 2019 B2
20010003798 McGovern Jun 2001 A1
20010007940 Tu Jul 2001 A1
20020091427 Rappaport Jul 2002 A1
20020147446 Ein-Gal Oct 2002 A1
20020173688 Chen Nov 2002 A1
20020193787 Qin et al. Dec 2002 A1
20030018256 Sasaki Jan 2003 A1
20030045909 Gross et al. Mar 2003 A1
20030055421 West Mar 2003 A1
20030069590 Rabiner Apr 2003 A1
20030013968 Fjield Jun 2003 A1
20040034339 Stoller Feb 2004 A1
20040038857 Tracey Feb 2004 A1
20040097788 Mourlas May 2004 A1
20040122494 Eggers et al. Jun 2004 A1
20040162507 Govari et al. Aug 2004 A1
20040162550 Govari et al. Aug 2004 A1
20040193021 Savage Sep 2004 A1
20050020921 Glassell Jan 2005 A1
20050080469 Larson et al. Apr 2005 A1
20050165298 Larson Jul 2005 A1
20050177209 Leung et al. Aug 2005 A1
20050192638 Gelfand Sep 2005 A1
20050203410 Jenkins Sep 2005 A1
20050222554 Wallace et al. Oct 2005 A1
20050251125 Pless Nov 2005 A1
20050288651 Van Tassel et al. Dec 2005 A1
20050288730 Deem et al. Dec 2005 A1
20060009753 Fjield et al. Jan 2006 A1
20060041277 Deem Feb 2006 A1
20060058711 Harhen et al. Mar 2006 A1
20060100514 Lopath May 2006 A1
20060184048 Saadat Aug 2006 A1
20060206150 Demarais Sep 2006 A1
20060212076 Demarais Sep 2006 A1
20060212078 Demarais Sep 2006 A1
20060241523 Sinelnikov et al. Oct 2006 A1
20060265014 Demarais Nov 2006 A1
20060265015 Demarais Nov 2006 A1
20060271111 Demarais Nov 2006 A1
20060276852 Demarais Dec 2006 A1
20060287648 Schwartz Dec 2006 A1
20070004984 Crum et al. Jan 2007 A1
20070021803 Deem Jan 2007 A1
20070038259 Kieval Feb 2007 A1
20070060972 Kieval Mar 2007 A1
20070093420 Yeomans Apr 2007 A1
20070112327 Lee May 2007 A1
20070129760 Demarais Jun 2007 A1
20070129761 Demarais Jun 2007 A1
20070133849 Young et al. Jun 2007 A1
20070135875 Demarais Jun 2007 A1
20070142879 Greenberg Jun 2007 A1
20070167984 Kieval Jun 2007 A1
20070162085 DiLorenzo Jul 2007 A1
20070167913 Elkins et al. Jul 2007 A1
20070173899 Levin et al. Jul 2007 A1
20070191906 Caparso Aug 2007 A1
20070203549 Demarais Aug 2007 A1
20070239077 Azhari et al. Oct 2007 A1
20070265610 Thapliyal et al. Nov 2007 A1
20070265687 Deem Nov 2007 A1
20070282407 Demarais Dec 2007 A1
20080004614 Burdette Jan 2008 A1
20080015445 Saadat Jan 2008 A1
20080033415 Rieker et al. Feb 2008 A1
20080039746 Francischelli Feb 2008 A1
20080058682 Azhari et al. Mar 2008 A1
20080058702 Arndt Mar 2008 A1
20080071173 Aldrich Mar 2008 A1
20080091109 Abraham Apr 2008 A1
20080108984 Burdette May 2008 A1
20080125819 Ben-David et al. May 2008 A1
20080140180 Dolan et al. Jun 2008 A1
20080172104 Kieval Jul 2008 A1
20080183248 Rezai Jul 2008 A1
20080215111 Kieval Sep 2008 A1
20080255449 Sinelnikov Oct 2008 A1
20080255642 Zarins Oct 2008 A1
20080281379 Wesselink Nov 2008 A1
20080288017 Kieval Nov 2008 A1
20080288031 Kieval Nov 2008 A1
20080306570 Rezai Dec 2008 A1
20080312521 Solomon Dec 2008 A1
20080319513 Pu Dec 2008 A1
20090024195 Rezai et al. Jan 2009 A1
20090048514 Azhari Feb 2009 A1
20090062790 Malchano Mar 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090076409 Wu Mar 2009 A1
20090112133 Deisseroth Apr 2009 A1
20090118780 DiLorenzo May 2009 A1
20090137900 Bonner et al. May 2009 A1
20090155336 Rezai Jun 2009 A1
20090157068 Kallel Jun 2009 A1
20090187230 DiLorenzo Jul 2009 A1
20090192506 Vaska et al. Jul 2009 A9
20090234407 Hastings et al. Sep 2009 A1
20090247912 Warnking Oct 2009 A1
20090270741 Vanney et al. Oct 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090287274 Ridder Nov 2009 A1
20090326511 Shivkumar Dec 2009 A1
20100004704 Mazgalev Jan 2010 A1
20100010567 Deem Jan 2010 A1
20100036292 Darlington et al. Feb 2010 A1
20100042170 Caparso Feb 2010 A1
20100105993 Hassan Apr 2010 A1
20100113928 Thapliyal May 2010 A1
20100130836 Malchano May 2010 A1
20100137860 Demarais Jun 2010 A1
20100137949 Mazgalev Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100145428 Cameron Jun 2010 A1
20100168624 Sliwa Jul 2010 A1
20100168731 Wu et al. Jul 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100174282 Demarais Jul 2010 A1
20100191112 Demarais Jul 2010 A1
20100204741 Tweden Aug 2010 A1
20100217162 Francischelli Aug 2010 A1
20100217369 Gross Aug 2010 A1
20100222851 Deem Sep 2010 A1
20100222854 Demarais Sep 2010 A1
20100234728 Foley Sep 2010 A1
20100256436 Partsch Oct 2010 A1
20100268297 Neisz Oct 2010 A1
20100305392 Gross et al. Dec 2010 A1
20100312094 Guttman et al. Dec 2010 A1
20110009734 Foley Jan 2011 A1
20110015548 Aldrich Jan 2011 A1
20110022133 Bradford Jan 2011 A1
20110040171 Foley Feb 2011 A1
20110040214 Foley Feb 2011 A1
20110060324 Wu Mar 2011 A1
20110092781 Gertner Apr 2011 A1
20110092880 Gertner Apr 2011 A1
20110112394 Mishelevich May 2011 A1
20110112400 Emery May 2011 A1
20110118598 Gertner May 2011 A1
20110118600 Gertner May 2011 A1
20110118725 Mayse May 2011 A1
20110137149 Gertner Jun 2011 A1
20110137298 Chen Jun 2011 A1
20110172527 Gertner Jun 2011 A1
20110172528 Gertner Jun 2011 A1
20110172529 Gertner Jun 2011 A1
20110178570 Demarais Jun 2011 A1
20110184337 Evans Jun 2011 A1
20110178541 Azhari Jul 2011 A1
20110184322 Brawer Jul 2011 A1
20110196248 Grunwald Aug 2011 A1
20110207758 Sobotka et al. Aug 2011 A1
20110208173 Sobotka et al. Aug 2011 A1
20110208175 Sobotka et al. Aug 2011 A1
20110251524 Azhari Oct 2011 A1
20110257523 Hastings et al. Oct 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110257641 Hastings et al. Oct 2011 A1
20110264075 Leung et al. Oct 2011 A1
20110264086 Ingle Oct 2011 A1
20110264116 Kocur et al. Oct 2011 A1
20110282203 Tsoref Nov 2011 A1
20110282249 Tsoref Nov 2011 A1
20110306851 Wang Dec 2011 A1
20120029500 Jenson Feb 2012 A1
20120029505 Jenson Feb 2012 A1
20120029509 Smith et al. Feb 2012 A1
20120029510 Haverkost Feb 2012 A1
20120029511 Smith et al. Feb 2012 A1
20120029512 Willard et al. Feb 2012 A1
20120029513 Smith et al. Feb 2012 A1
20120089047 Ryba et al. Apr 2012 A1
20120095371 Sverdlik et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120101538 Ballakur et al. Apr 2012 A1
20120116382 Ku et al. May 2012 A1
20120130363 Kim May 2012 A1
20120150049 Zielinski et al. Jun 2012 A1
20120157992 Smith et al. Jun 2012 A1
20120172680 Gelfand et al. Jul 2012 A1
20120191079 Moll et al. Jul 2012 A1
20120197198 Demarais Aug 2012 A1
20120197243 Sherman et al. Aug 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120265227 Sverdlik et al. Oct 2012 A1
20120290024 Zhang et al. Nov 2012 A1
20120296240 Azhari Nov 2012 A1
20120296329 Ng Nov 2012 A1
20130012866 Deem Jan 2013 A1
20130013024 Levin Jan 2013 A1
20130085489 Fain et al. Apr 2013 A1
20130103028 Tsoref Apr 2013 A1
20130131743 Yamasaki et al. May 2013 A1
20130165926 Mathur Jun 2013 A1
20130204242 Sverdlik et al. Aug 2013 A1
20130211396 Sverdlik et al. Aug 2013 A1
20130211437 Sverdlik et al. Aug 2013 A1
20130218029 Cholette et al. Aug 2013 A1
20130218054 Sverdlik et al. Aug 2013 A1
20130218068 Sverdlik et al. Aug 2013 A1
20130231655 Budzelaar et al. Sep 2013 A1
20130274614 Shimada et al. Oct 2013 A1
20130274735 Hastings et al. Oct 2013 A1
20130289369 Margolis Oct 2013 A1
20130303876 Gelfand et al. Nov 2013 A1
20130310674 Deno et al. Nov 2013 A1
20130310823 Gelfand et al. Nov 2013 A1
20130321262 Schecter Dec 2013 A1
20130322724 Florent et al. Dec 2013 A1
20130324987 Leung et al. Dec 2013 A1
20130324989 Leung et al. Dec 2013 A1
20130331813 Barbut et al. Dec 2013 A1
20140005706 Gelfand et al. Jan 2014 A1
20140012133 Sverdlik et al. Jan 2014 A1
20140018788 Engelman et al. Jan 2014 A1
20140088561 Levin et al. Mar 2014 A1
20140128865 Gross May 2014 A1
20140194866 Wang Jul 2014 A1
20140213873 Wang Jul 2014 A1
20140221805 Wang Aug 2014 A1
20140243809 Gelfand et al. Aug 2014 A1
20140257263 Azamian et al. Sep 2014 A1
20140276036 Collins et al. Sep 2014 A1
20140276063 Park et al. Sep 2014 A1
20140276742 Nabutovsky et al. Sep 2014 A1
20140288551 Bharmi et al. Sep 2014 A1
20150011843 Toth et al. Jan 2015 A1
20150045649 O'Dea et al. Feb 2015 A1
20150073400 Sverdlik et al. Mar 2015 A1
20150148601 Weiner et al. May 2015 A1
20150164401 Toth et al. Jun 2015 A1
20150173673 Toth et al. Jun 2015 A1
20150216590 Wang et al. Aug 2015 A1
20150224326 Toth et al. Aug 2015 A1
20150245867 Gross Sep 2015 A1
20150257779 Sinelnikov et al. Sep 2015 A1
20150289929 Toth et al. Oct 2015 A1
20150297113 Kassab et al. Oct 2015 A1
20150297139 Toth Oct 2015 A1
20160000499 Lennox et al. Jan 2016 A1
20160106498 Highsmith et al. Apr 2016 A1
20160113699 Sverdlik et al. Apr 2016 A1
20160128767 Azamian et al. May 2016 A1
20160324572 Gross et al. Nov 2016 A1
20160338773 Shimada et al. Nov 2016 A1
20170007157 Gross et al. Jan 2017 A1
20170007158 Gross et al. Jan 2017 A1
20170027460 Shimada et al. Feb 2017 A1
20170035310 Shimada et al. Feb 2017 A1
20170056104 Asirvatham et al. Mar 2017 A1
20170172651 Gross et al. Jun 2017 A1
20170215950 Gross et al. Aug 2017 A1
20180168720 Jensen Jun 2018 A1
20180221087 Puryear et al. Aug 2018 A1
20180280082 Puryear et al. Oct 2018 A1
20180303536 Kafiluddi Oct 2018 A1
Foreign Referenced Citations (34)
Number Date Country
2900160 Aug 2014 CA
2956945 Feb 2016 CA
102551878 Jul 2012 CN
203089369 Jul 2013 CN
2460486 Jun 2012 EP
199940957 Aug 1999 WO
03097162 Nov 2003 WO
2006072928 Jul 2006 WO
07134258 Nov 2007 WO
2008003058 Jan 2008 WO
2009073208 Jun 2009 WO
2010067360 Jun 2010 WO
2011024159 Mar 2011 WO
2011141918 Nov 2011 WO
2012100211 Jul 2012 WO
2012120495 Sep 2012 WO
2012122157 Sep 2012 WO
2013030738 Mar 2013 WO
2013030743 Mar 2013 WO
2013049601 Apr 2013 WO
2013111136 Aug 2013 WO
2013121424 Aug 2013 WO
2013157009 Oct 2013 WO
2014029355 Feb 2014 WO
2014068577 May 2014 WO
2014071223 May 2014 WO
2014123512 Aug 2014 WO
2014145853 Oct 2014 WO
2014160832 Oct 2014 WO
2015057696 Apr 2015 WO
2015138225 Sep 2015 WO
2015170281 Nov 2015 WO
2015175948 Nov 2015 WO
2017199240 Nov 2017 WO
Non-Patent Literature Citations (160)
Entry
Buch E et al., “Intra-pericardial balloon retraction of the left atrium: A novel method to prevent esophageal injury during catheter ablation,” Heart Rhythm 2008;5:1473-1475.
Cassak D, “Endosense: Facing technology and financing challenges in AF,” IN-VIVO: The Business & Medicine Report, 36-44, Mar. 2010.
Di Biase L et al., “Prevention of phrenic nerve injury during epicardial ablation: Comparison of methods for separating the phrenic nerve from the epicardial surface,” Heart Rhythm 2009;6:957-961.
Matsuo S et al., “Novel technique to prevent left phrenic nerve injury during epicardial catheter ablation,” Circulation 2008;117:e471.
Nakahara S et al., “Intrapericardial balloon placement for prevention of collateral injury during catheter ablation of the left atrium in a porcine model,” Heart Rhythm 2010;7:81-87.
Shen J et al., “The surgical treatment of atrial fibrillation Heart Rhythm,” vol. 6, No. 8S, Aug. Supplement 2009.
Sacher F et al “Phrenic Nerve Injury After Catheter Ablation of Atrial Fibrillation,” Indian Pacing Electrophysiol J. Jan.-Mar. 2007; 7(1): 1-6.
A Restriction Requirement dated Feb. 25, 2013, which issued during the prosecution of U.S. Appl. No. 12/780,240.
Tanaka S et al., “Development of a new vascular endoscopic system for observing inner wall of aorta using intermittent saline jet” World Congress on Medical Physics and Biomedical Engineering, Sep. 7-12, 2009, Munich, Germany.
Tearney GJ et al., “Three-Dimensional coronary artery microscopy by intracoronary optical frequency domain imaging” JACC Cardiovasc Imaging. Nov. 2008; 1(6): 752-761.
An Office Action dated Aug. 21, 2015, which issued during the prosecution of U.S Appl. No. 13/771,853.
William E. Cohn, et al., “Contrast pericardiography facilitates intrapericardial navigation under fluoroscopy”, Ann Thorac Surg 2010; 90: 1537-40. Accepted for publication Jun. 7, 2010.
Srijoy Mahapatra, et al., “Pressure frequency characteristics of the pericardial space and thorax during subxiphoid access for epicardial ventricular tachycardia ablation”, Heart Rhythm 2010; 7:604-609.
Schuessler RB et al., “Animal studies of epicardial atrial ablation,” Heart Rhythm, vol. 6, No. 12S, S41-S45, Dec. Supplement 2009.
An English translation of an Office Action dated Nov. 18, 2016, which issued during the prosecution of Chinese Patent Application No. 2013800692612.
An International Search Report and Written Opinion both dated Oct. 26, 2011, which issued during the prosecution of Applicant's PCT/IL11/00382.
An International Search Report and a Written Opinion both dated Sep. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000100.
An International Preliminary Report on Patentability dated Nov. 20, 2012, which issued during the prosecution of Applicant's PCT/IL11/00382.
An International Search Report dated Jul. 31, 2008, which issued during the prosecution of Applicant's PCT/US07/68818.
An Office Action dated Dec. 20, 2012, which issued during the prosecution of U.S. Appl. No. 11/653,115.
An Office Action dated Feb. 19, 2013, which issued during the prosecution of U.S. Appl. No. 13/010,555.
Fajardo et al., Effects of Hyperthermia in a Maligant Tumor, Cancer 45:613-623 (1980).
Short et al., Physical Hyperthermia and Cancer Therapy, Proceedings of the IEEE 68:133-142 (1980) p. 136 col. 2, para 6.
U.S. Appl. No. 60/370,190, filed Apr. 8, 2002.
U.S. Appl. No. 60/307,124, filed Jul. 23, 2001.
An Office Action dated May 17, 2013, which issued during the prosecution of U.S. Appl. No. 12/780,240.
An Invitation to pay additional fees dated Jun. 7, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050134.
An International Search Report and a Written Opinion both dated Aug. 12, 2013 which issued during the prosecution of Applicant's PCT/IL2013/050134.
An International Search Report and a Written Opinion both dated Feb. 18, 2011 which issued during the prosecution of Applicant's PCT/IL2010/000683.
An International Preliminary Report of patentability dated Feb. 28, 2012 which issued during the prosecution of Applicant's PCT/IL2010/000683.
F. Mahfoud et al., Catherter-Based renal denervation increases insulin sensitivity and improves glucose metabolism. European Heart Journal 2010.
F. Mahfoud et al., Effects of Renal Sympathetic Denervation on Glucose Metabolism in Patients with Resistant Hypertension: A Pilot Study. Circulation 2011: 123 1940-1946.
Tai et al., Analysis of Nerve Conduction Including by Direct Current, J Comput Neuro. Published Online on 2009.
Ariav et al., Electrical Stimulation Induced Relaxation of Isolated Pig Aortas, Scientific Sessions 2011. American Heart Association.Abstract.
Stella et al., Cardiovascular Effects of Efferent renal nerve stimulation, Clin and Exper. Theory and Practice, 97-111, 1987.
Mortimer and Bhadra., Peripheral Nerve and Muscle Stimulation, Chapter 4.2, 1-48, 2004.
Stella et al., Effects of afferent renal nerve stimulation on renal hemodynamic and excretory functions, American Journal of physiology, 576-583, 1984.
Renal Sympathetic denervation in patients with treatment resistant hypertension, (1-7) Published online Nov. 2010.
Zhang et al., Mechanism of Nerve conduction Block induced by High-Frequency Biphasic Electrical Currents, IEEE Biomedical Engineering vol. 53 No. 12, 2006.
Bhadra et al., Reduction of the Onset Response in High-Frequency Nerve Block with Amplitude Ramps from Non-Zero Amplitudes, 650-653, 2009 IEEE.
Tai et al., Stimulation of Nerve Block by High-Frequency Sinusoidal Electrical Current Based on the Hodgkin-Huxley Model, IEEE Neural Systems and Rehabilitation engineering, vol. 13 No. 3, 2005.
Tsui, Electrical Nerve Stimulation, Springer Atlas of Ultrasound, pp. 9-18, 2008.
Bartus et al., Denervation (ablation) of Nerve Terminalis in renal arteries: early results of interventional treatment of arterial hypertension in Poland, Kardiologia Polska 2013, 71, 2: 152-158.
Krum et al., Catherter-Based Renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study, Lancet 2009.
Chinushi M. et al., Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerve before and after ablation of the renal artery, Pubmed, Hyper tension, Feb. 2013 61;(2) 450-6.
Wojakowski and Tendera, Renal sympathetic nerve in pathopysiology of resistant hypertension, European Society of Cardiology, downloaded on Jun. 2013.
Chinushi et al., Hemodynamic Responses and Histological Effects of Radiofrequency catheter Ablation to renal artery Sympathetic nerve. Abstract, downloaded on Jun. 2013.
Berjano, Biomedical Engineering Online Theoretical modeling for Radiofrequency Ablation: state-of-the-art and challenges for the future, published Apr. 2006.
Young and Henneman, Reversible block of nerve Conduction by Ultrasound, Archive of Neurology vol. 4, 1961.
Ballantine et al., Focal Destruction of nervous tissue by focused ultrasound : Biophysical factors influencing its Application, Medical Acoustics Research Group, 1956.
Colucci et al., Focused Ultrasound effects on nerve action potential in vitro, Department of Radiology, Harvard Medical Scholl, Ultrasound Med Biolog. 2009, 35(10); 1773-1747.
Damianou, MRI Monitoring of the effects of tissue interfaces in the penetration of high intensity focused ultrasound in kidney in vivo, Ultrasound in Med & Bilo., vol. 30 No. 9, 2004.
Daum et al., In vivo Demonstration of noninvasive thermal surgery of the liver and kidney using an ultrasonic phase array, Ultrasound in Med & Bilo., vol. 25 No. 7, 1087-1098, 1999.
Foley et al., Image guided HIFU Neurolysis of peripheral nerve to treat Spasticity and Pain, Ultrasound in Med & Bilo., vol. 30 No. 9, 1199-1207, 2004.
Foley et al., Image guided High-Intensity focused Ultrasound for Condition block of peripheral nerves, Biomed Engineering, vol. 35 No. 1, 2007.
Zhang and Solomon, Nerve Ablation by high Intensity focused Ultrasound (HIFU) in swine model: Investigating HIFU as a non invasive Nerve block tool, WCIO 2011. Abstract.
Hynynen et al., Noninvasive arterial occlusion using MRI-Guided focused Ultrasound, Ultrasound in Med & Bilo., vol. 22 No. 8, 1071-1077, 1996.
Iwamoto et al., focused Ultrasound for Tactile Felling display, ICAT 2001.
Lele, Effects of Ultrasonic radiation on peripheral Nerve, with Observation on local Hearting, Experimental Neurology 8, 47-83, 1963.
Miharn et al., Temporally-Specific modification of Myelinated Axon excitability in vitro following a single ultrasound pulse,Ultrasound in Med & Bilo., 1990.
Rubin et al., Acute effects of Ultrasound on skeletal muscle oxygen tension , blood flow and capillary density, Ultrasound in Med & Bilo., vol. 16 No. 3, 271*277, 1990.
Renal sympathetic nerve ablation for Uncontrolled Hypertension, The New England journal of medicine, 932-934, 2009.
Wu et al., Preliminary Experience using high Intensity focused Ultrasound for the treatment of patient with advanced stage renal malignancy. The Journal of Urology, vol. 170, 2237-2240, 2003.
Young and Henneman, Functional Effects of focused Ultrasound on Mammalian nerves, Science New Series, vol. 134, No. 3489, 1961, 1521-1522.
Mizelle et al., Role of Renal nerve in Compensatory adaptation to chronic reduction in sodium intake, American Physiological Society, 1987.
Gibson, The Present Status of Renal Sympathectomy, California and Western Medicine, vol. 45, No. 1, 1936.
Kassab et al., Renal Denervation Attenuates the Sodium Retention and Hypertension Associated With Obesity, Hypertension, 1995. Abstract.
Winternitz et al., Role of the Renal Sympathetic Nerves in the Development and Maintenance of Hypertension in the Spontaneously Hypertensive Rat, J. Clin Invest 66(5), 1980. Abstract.
Augustyniak et al., Sympathetic overactivity as a cause of hypertension in chronic renal failure, Hypertension vol. 20, Issue 1, 2002. Abstract.
Brief introduction to bioimpedance (from www.ucl.ac.uk-medphys-research-eit).
Fletcher, Effect of episodic hypoxia on sympathetic activity and blood pressure, Respyration Pysiology, vol. 119, issue 2-3, 2000. Abstract.
Fletcher et al., Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system, Journal of Applied physiology, 2001.
Illis, Spinal Cord Synapses in the CAT: The Reaction of the Boutons Termineaux at the Motoneurone Surface to Experimental Denervation, Brain a Journal of Neurology, vol, 87 issue 3, 1963, First page only.
Kopelman et al., Upper dorsal thoracoscopic sympathectomy for palmar hyperhidrosis. The use of hamionic scalpel versus diathermy. Ann Chir Gynaecol. 2001:90(3):203-5. Abstract.
Hashmonai et al., Thoracoscopic sympathectomy for palmar hyperhidrosis, Surgical Endoscopy May 2001, vol. 15, Issue 5, pp. 435-441. Abstract.
Yoshimoto et al., Relationship between renal sympathetic nerve activity and renal blood flow during natural behavior in rats, American Journal of Physiology vol. 286, 2004.
DiBona. Dynamic Analysis of patterns of renal sympathetic nerve activity: Implications of renal functions, Exp Physiol. 90.2 pp. 159-161, 2004.
Valente et al., Laparoscopic renal denervation for intractable ADPKD-related pain, Nephrology Dialysis Transplantation vol. 6 issue 1, 2000.
An International Search Report and a Written Opinion both dated Aug. 11, 2015 which issued during the prosecution of Applicant's PCT/IB2015/053350.
An International Preliminary Report on Patentability dated Nov. 8, 2016, which issued during the prosecution of Applicant's PCT/IB2015/053350.
An Advisory Action dated Aug. 8, 2016, which issued during the prosecution of U.S. Appl. No. 13/771,853.
European Search Report dated Jun. 7, 2016, which issued during the prosecution of Applicant's European App No. 13850508.6.
U.S. Appl. No. 61/811,880, filed Apr. 15, 2013.
Schwarz et al;(2015) Autonomix presentation at TCT—Guidewire-Based Autonomic Neural Sensing From the Artery Lumen.
An International Search Report and a Written Opinion both dated Apr. 17, 2014 which issued during the prosecution of Applicant's PCT/IL2013/050903.
Luscher TF, Mahfoud F. Renal nerve ablation after symplicity htn-3: Confused at the higher level? Eur Heart J. 2014;35:1706-1711.
Lu (2015) Selective Proximal Renal Denervation Guided by Autonomic Responses Evoked via High-Frequency Stimulation in a Preclinical Canine Model.
Straub et al., ‘A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-a and IL-6 secretion in the spleen’ Jul. 2000 The FASEB Journal vol. 14 No. 10 1380-1388.
Gestel et al., ‘Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD)’ J Thorac Dis 2010; 2:215-222.
Hering et al., ‘Renal Denervation in Moderate to Severe CKD’ J Am Soc Nephrol. [Jul. 2012]; 23(7): 1250-1257.
Jonson et al, ‘Afferent electrical stimulation of mesenteric nerves inhibits duodenal HC03 secretion via a spinal reflex activation of the splanchnic nerves in the rat’ [1988] Acta Physiologica Scandinavica, 133: 545-550. doi: 10.1111/j.1748-1716.1988.tb08439.x.
Jonson et al., ‘Splanchnic nerve stimulation inhibits duodenal HC03-secretion in the rat’ Am J Physiol. [Dec. 1988];255 (6 Pt 1):G709-12.
Schwan, H.P. And Kay, C.F., 1956. Specific resistance of body tissues.Circulation Research, 4(6), pp. 664-670.
Kees et al., ‘Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharideinduced TNF secretion in perfused rat spleen’ J Neuroimmunol. Dec. 2003;145(1-2):77-85.
pcta.org, ‘New (Dec. 6, 2013) Medtronic Multi-Electrode Renal Denervation Device Gets CE Mark and Australian Approval’ http://www.ptca.org/news/2013/1206_MEDTRONIC_SYMPLICITY.html.
BusinessWire, ‘St. Jude Medical Receives European Approval for New Renal Denervation System That Reduces Total Ablation Time by More Than 80 Percent’ (Aug. 29, 2013) 2013 European Society of Cardiology.
mananatomy.com, ‘Duodenum’ http://www.mananatomy.com/digestive-system/duodenum.
Rosas-Ballina et al., ‘Splenic nerve is required for cholinergic anti-inflammatory pathway control of TNF in endotoxemia’ Aug. 5, 2008, vol. 105, No. 31 www.pnas.org/cgi/doi10.1073/pnas.0803237105.
Krum, H., et al. “Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system.” Circulation 123.2 (2011): 209.
Kilgore, Kevin L., et al. “Combined direct current and high frequency nerve block for elimination of the onset response.” Engineering in Medicine and Biology Society, 2009. EMBC 2009. Annual International Conference of the IEEE. IEEE, 2009.
Bohm (2014) Symplicity HTN-3 trial_ what is it and what does it mean?.
Ruilope (2014) Was there real denervation in the Symplicity HTN-3 trial.
Esler (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial).
Renal Catheterization—SymplicityTM Renal Denervation System—downloaded from medtronicrdn.com Jun. 26, 2013.
An Office Action dated Mar. 11, 2016, which issued during the prosecution of U.S. Appl. No. 13/771,853.
Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after symplicity htn-3: An update. Curr Hypertens Rep. 2014;16:460.
Renal denervation and symplicity htn-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115:211-214.
Patel HC, Hayward C, Di Mario C. Symplicity htn 3: The death knell for renal denervation in hypertension? Glob Cardiol Sci Pract. 2014;2014:94-98.
An Office Action dated Jan. 8, 2015, which issued during the prosecution of U.S. Appl. No. 13/771,853.
An International Preliminary Report on Patentability dated Ma 5, 2015, which issued during the prosecution of Applicant's PCT/IL2013/050903.
U.S. Appl. No. 61/841,485, filed Jul. 1, 2013.
Changfeng (2009) Analysis of nerve conduction block induced by direct current.
Tsui (2008) Chapter 2 of Atlas of ultrasound and nerve stimulation guided regional anesthesia.
Changfeng (2005) Simulation of nerve block by high frequency sunusoidal electrical current.
Warchol-Celinska E, Januszewicz A, Prejbisz A, Kadziela J. Renal denervation after the symplicity htn-3 trial. Postepy Kardiol Interwencyjnej. 2014;10:75-77.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research Circulation. 2008.
Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: Novel implications for an old concept. Hypertension. 2009;54:1195-1201.
Esler MD, Bohm M, Sieved H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the Symplicity htn-2 randomized clinical trial. Eur Heart J. 2014;35:1752-1759.
U.S. Appl. No. 61/862,561, filed Aug. 6, 2013.
U.S. Appl. No. 61/722,293, filed Nov. 5, 2012.
“Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study”, Gal et al., Journal of Human Hypertension (2014), 1-4, Macmillan Publishers Limited.
Sarafidis PA, Bakris GL. Resistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749-1757.
Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-424.
Kjeldsen SE, Fadl Elmula FE, Persu A, Jin Y, Staessen JA. Renal sympathetic denervation in the aftermath of symplicity htn-Blood Press. 2014;23:256-261.
Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: Rationale and design of the symplicity htn-3 trial. Clin Cardiol. 2012;35:528-535.
European Search Report dated May 9, 2017, which issued during the prosecution of Applicant's European App No. 16203956.4.
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the symplicity htn-1 study. Lancet. 2014;383:622-629.
Esler M. Illusions of truths in the symplicity htn-3 trial: Generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8:593-598.
Schmieder RE. Hypertension: How should data from symplicity htn-3 be interpreted? Nat Rev Cardiol. 2014;11:375-376.
Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, Schlaich M, Schmieder R, Tsioufis K, Ukena C, Zeller T. From symplicity htn-3 to the renal denervation global registry: Where do we stand and where should we go? Eurointervention. 2014;10:21-23.
Pokushalov, Evgeny, et al. “A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension.” Journal of the American College of Cardiology 60.13 (2012): 1163-1170.
Ruilope, L.M. and Arribas, F., 2014. Resistant Hypertension and Renal Denervation. Considerations on the Results of the Symplicity HTN-3 Trial.Reyista Española de Cardiología, 67(11), pp. 881-882.
An Office Action dated Apr. 6, 2017, which issued during the prosecution of U.S. Appl. No. 13/771,853.
U.S. Appl. No. 61/989,741, filed May 7, 2014.
U.S. Appl. No. 62/158,139, filed May 7, 2015.
An Office Action dated Nov. 30, 2017, which issued during the prosecution of U.S. Appl. No. 14/794,737.
An Office Action dated Dec. 15, 2017, which issued during the prosecution of U.S. Appl. No. 14/795,529.
An International Search Report and a Written Opinion both dated Dec. 14, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050967.
An International Search Report and a Written Opinion both dated Nov. 10, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050533.
An Office Action dated Jan. 14, 2019, which issued during the prosecution of U.S. Appl. No. 14/972,756.
An International Search Report and a Written Opinion both dated May 24, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050029.
An Invitation to pay additional fees dated Mar. 28, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050029.
Notice of Allowance together with the English translation dated May 4, 2017 which issued during the prosecution of Chinese Patent Application No. 2013800692612.
An Office Action dated Jun. 15, 2017, which issued during the prosecution of U.S Appl. No. 14/440,431.
An Invitation to pay additional fees dated Sep. 11, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050533.
Notice of Allowance dated Jan. 22, 2018, which issued during the prosecution of U.S. Appl. No/ 14/440,431.
Notice of Allowance dated May 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/440,431.
Notice of Allowance dated Jun. 21, 2019, which issued during the prosecution of U.S. Appl. No. 15/147,081.
Notice of Allowance dated Mar. 15, 2019, which issued during the prosecution of U.S. Appl. No. 15/147,081.
An Advisory Action dated Apr. 18, 2019, which issued during the prosecution of U.S. Appl. No. 14/972,756.
An International Preliminary Report on Patentability dated Nov. 20, 2018, which issued during the prosecution of Applicant's PCT/IL2017/050533.
An Office Action dated May 15, 2018, which issued during the prosecution of U.S. Appl. No. 14/972,756.
An Office Action dated Jul. 19, 2018, which issued during the prosecution of U.S. Appl. No. 15/147,081.
An International Search Report and a Written Opinion both dated Jun. 11, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050231.
Notice of Allowance dated Aug. 20, 2019, which issued during the prosecution of U.S. Appl. No. 15/330,790.
An Office Action dated Sep. 6, 2018, which issued during the prosecution of U.S. Appl. No. 15/001,615.
Notice of Allowance dated Aug. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/330,790.
An Office Action dated Feb. 21, 2019, which issued during the prosecution of U.S. Appl. No. 15/330,790.
Notice of Allowance dated May 24, 2019, which issued during the prosecution of U.S. Appl. No. 15/147,081.
U.S. Appl. No. 62/338,115, filed May 18, 2016.
Related Publications (1)
Number Date Country
20200179044 A1 Jun 2020 US
Provisional Applications (1)
Number Date Country
62338115 May 2016 US